Novo Nordisk Gives Unclear Answer On Participation In Medicare Negotiations Round Two

Novo Nordisk would not say whether it has agreed to participate in the second round of Medicare drug price negotiations under the Inflation Reduction Act, while reiterating to Inside Health Policy its position that CMS’ decision to group its selected GLP-1 drugs as a single item does not meet the requirements of the statute. But Pfizer, Astellas, GlaxoSmithKline, Bristol Myers Squibb, AstraZeneca and Amgen confirmed to Inside Health Policy they have agreed to participate in the second round...